Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of INO-4212 and Its Components, INO-4201 and INO-4202, Given With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers

Trial Profile

Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of INO-4212 and Its Components, INO-4201 and INO-4202, Given With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs INO 4212 (Primary)
  • Indications Ebola virus infections
  • Focus Adverse reactions
  • Sponsors Inovio Pharmaceuticals
  • Most Recent Events

    • 11 Apr 2017 According to an Inovio Pharmaceuticals media release, the company presented data from this study at the World Vaccine Congress.
    • 11 Apr 2017 According to an Inovio Pharmaceuticals media release, the company announced preliminary results from the expanded stage of this phase I study.
    • 11 Apr 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top